Advertisement
Screener

EQUILLIUM, INC. (EQ) Proceeds from Stock Options Exercised

2.8 / 5 stars · 68/120 Roast Me

EQUILLIUM, INC. Proceeds from Stock Options Exercised

EQUILLIUM, INC. (EQ) reported Proceeds from Stock Options Exercised of $583.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Financing Activities

us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-13

  • EQUILLIUM, INC. proceeds from stock options exercised for the quarter ending 2026-06-30 was $135.00K.
  • EQUILLIUM, INC. proceeds from stock options exercised for the quarter ending 2026-03-31 was $448.00K, a 1078.95% increase year-over-year.
  • EQUILLIUM, INC. proceeds from stock options exercised for the quarter ending 2025-12-31 was $604.00K.
  • EQUILLIUM, INC. proceeds from stock options exercised for the quarter ending 2025-09-30 was $1.19M.
  • EQUILLIUM, INC. proceeds from stock options exercised for fiscal 2025 was $1.84M, a 45800.00% increase from fiscal 2024.
  • EQUILLIUM, INC. proceeds from stock options exercised for fiscal 2024 was $4.00K.
  • EQUILLIUM, INC. proceeds from stock options exercised for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
  • EQUILLIUM, INC. proceeds from stock options exercised for fiscal 2021 was $891.00K, a 12628.57% increase from fiscal 2020.
Period endProceeds from Stock Options Exercised 3 monthProceeds from Stock Options Exercised 6 monthProceeds from Stock Options Exercised 9 monthProceeds from Stock Options Exercised 12 monthProceeds from Stock Options Exercised 12 month as first filed
2026-06-30$135.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$583.00K
10-Q · filed 2026-08-13
$1.19M
derived: sum of 3 quarters · filed 2026-08-13
$2.38M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$448.00K
10-Q · filed 2026-05-13
$1.05M
derived: sum of 2 quarters · filed 2026-05-13
$2.25M
derived: sum of 3 quarters · filed 2026-05-13
$2.25M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$604.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
$1.80M
derived: sum of 2 quarters · filed 2026-03-25
$1.80M
derived: sum of 3 quarters · filed 2026-08-13
$1.84M
10-K · filed 2026-03-25
2025-09-30$1.19M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$1.19M
derived: sum of 2 quarters · filed 2026-08-13
$1.23M
10-Q · filed 2025-11-13
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$38.00K
10-Q · filed 2026-08-13
2025-03-31$38.00K
10-Q · filed 2026-05-13
2024-12-31$4.00K
10-K · filed 2026-03-25
2022-12-31$0.00
10-K · filed 2023-03-23
2021-12-31$91.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23
$265.00K
derived: sum of 2 quarters · filed 2023-03-23
$887.00K
derived: sum of 3 quarters · filed 2023-03-23
$891.00K
10-K · filed 2023-03-23
2021-09-30$174.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$796.00K
derived: sum of 2 quarters · filed 2022-11-14
$800.00K
10-Q · filed 2022-11-14
2021-06-30$622.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
$626.00K
10-Q · filed 2022-08-15
2021-03-31$4.00K
10-Q · filed 2022-05-12
2020-12-31$7.00K
10-K · filed 2022-03-23
2019-12-31$69.00K
10-K · filed 2021-03-24
2018-12-31$291.00K
10-K · filed 2020-03-26
$291.09K
10-K · filed 2019-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
GENELUX Corp (GNLX)United States$0.110B-3.83
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49